RecruitingNot ApplicableNCT06428721

The Preventive Role of Fractionated Laser Resurfacing Against Actinic Neoplasia in an At-Risk Geriatric Population


Sponsor

Wright State University

Enrollment

80 participants

Start Date

Mar 20, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to determine if the Fractionated Laser Resurfacing (FLR) procedure can protect one forearm/wrist from precancerous actinic keratosis (AKs) as well as prevent skin cancer in older subjects with active AKs. This study builds on a similar study ongoing at the Dayton Veterans Administration dermatology clinic. This study is also testing if a photograph of the skin can be used to predict where the AKs and an skin cancers will form.


Eligibility

Min Age: 60 Years

Inclusion Criteria5

  • Adult Males and Females aged 60 and older
  • Have at least 5 AKs on each forearm/wrist, but no more than 10 to allow for easy monitoring
  • Skin type fair (Fitzpatrick I-II)
  • Females must be post-menopausal and not be on systemic hormone replacement therapy
  • Able to comprehend procedures and risks

Exclusion Criteria10

  • More than 10 AKs on an extremity
  • AKs that are large (2-3+, hyperkeratotic grade 3 lesions)
  • AKs that are very thick (\>3 mm)
  • Medical history of diabetes
  • History of poor wound healing or scarring
  • Large tattoos that can interfere with study
  • Other serious health issues and other skin diseases that could interfere with the study
  • Recent (within 1 year) field therapies such as efudex cream or PDT to forearms/wrists.
  • Planning to leave region in next 5 years
  • Subjects with allergies to xylocaine will be excluded if they need this topical anesthetic.

Interventions

DEVICEFractionated Laser Resurfacing

A rejuvenating laser that makes tiny holes in the very superficial part of the skin.


Locations(1)

Wright State Physicians

Fairborn, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06428721


Related Trials